

. . . , . . .

( - . . . . . ), . . .

**STUDYING THE INFLUENCE OF NEUROTROPIC DRUGS ON ENZIMATIC SYSTEMS OF ACTIVE OXYGEN FORMS REDUCTION FOR OPTIC NERVE AND RETINA DURING EXPERIMENTAL GLAUCOMA**

V. N. Serdyuk, N. . . Malaya

**SUMMARY**

Adult rabbits with experimental glaucoma were used in this study. We studied superoxide dismutase and catalase activity in the eye tissue during glaucoma process. Results suggest decrease activity of both ferments, compared to normal ranges. This influence was significantly prevented using neuroprotective drugs.

. . . , . . .

i i i i i i

70

[1,9,16].

[2,7,17,19].

60

( . . . ).

[3,6,10,12,13,18,20].

( - . . . , -

, )

0,5 %

[4,14].

( - ) -

0,15

NMDA-

( )

[11,15].

(100 )

[8].

( ):

55 ( 2,5-3,2 ).

3 :1 — ( ) -

,2 — ( 0,02

),3 — ( 3

); :1- -3 ), ,2- -5 ,0,33 ,0,01 N-

-6 ,3- -10 . : -5 /

, -100 / 540 ,

0,1 0,8

10 ,

50 %

( , 6,2%.

),

50 / ,

		1	2	3	
( . / )	n	9	8	7	8
	M	37,56	33,88	30,00	26,25
	m	1,81	1,33	1,31	0,75
	p	-	>0,05	<0,01	<0,0001
	%	100	90,2	79,9	69,9
	1	-	-	-	-
	%1	-	100	100	100
	n	9	8	7	8
	M	37,56	41,32	39,44	33,82
	m	1,81	1,50	1,72	1,30
	p	-	>0,05	>0,05	>0,05
	%	100	110,0	105,0	90,0
	1	-	<0,01	<0,001	<0,001
	%1	-	122,0	131,5	128,8
( / )	n	9	8	7	8
	M	510,56	483,75	467,14	422,50
	m	6,43	10,68	9,93	11,46
	p	-	<0,05	<0,01	<0,00001
	%	100	94,7	91,5	82,8
	1	-	-	-	-
	%1	-	100	100	100
	n	9	8	7	8
	M	510,56	500,35	510,80	536,38
	m	6,43	12,40	11,32	12,20
	p	-	>0,05	>0,05	>0,05
	%	100	98,0	100,0	105,1
	1	-	>0,05	<0,05	<0,001
	%1	-	101,4	109,3	127,0

t- : - ; 1 - «

0,1 [5].  
 7,8) 2 0,03 % 0,05 - Cl- ( 0,1  
 10 1 4% - 1.  
 410 « -210» - ,  
 2 , 1  
 / . 8,7%. 33,88±1,33 . / ,  
 90,2%. 2 - 30,0±1,31 . / (79,9%),



- 
12. Lagreze W. A., Otto T., Feuerstein T. J. Neuroprotection in ischemia of the retina an animal model // *Ophthalmologie*. - 1999. - Vol. 96. - 6. - P. 370-374.
13. Moreno M. C., Marcos H. A. A new experimental model of glaucoma in rats through intracameral injection of hyaluronic acid / *Exp. Eye Res.* - 2005.
14. Ritch R., Shields M., Krupin T. *The Glaucomas*. - St. Luis: CV Mosby, 1996.- 432 p.
15. Schroder A., Erb C. Einsatz von memantine bei glaucoma fere absolutum // *Klin. Monatsbl. Augenheilkd.* - 2002. - Vol. 219. - P. 533-536.
16. Sommer A. Intraocular pressure and glaucoma // *Am. J. Ophthalmol.* - 1989. - Vol. 107, 2. - P. 186 - 188.
17. Tezel G. Accelerated aging in glaucoma: immunohistochemical assessment of advanced glycation end products in the human retina and optic nerve head / Tezel G., Luo G., Yang X. // *Invest. Ophthalmol. Vis. Sci.* - 2007. - Vol. 48. - P. 1201-1211.
18. Tezel G. Clinical factors associated with progression of glaucomatous optic disc damage in treated patients / Tezel G., Siegmund K. D., Trinkaus K. // *Arch. Ophthalmol.* - 2001. - Vol. 119. - P. 813-818.
19. Tezel G. The role of glia, mitochondria, and the immune system in glaucoma / Tezel G. // *Invest. Ophthalmol. Vis. Sci.* - 2009. - Vol. 50. - 3. - P. 1001-1012.
20. Wiggs J. L. Genetic etiologies of glaucoma / Wiggs J. L. // *Arch. Ophthalmol.* - 2007. - Vol. 125. - 1. - P. 30-37.